全文获取类型
收费全文 | 5773篇 |
免费 | 578篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 46篇 |
儿科学 | 210篇 |
妇产科学 | 253篇 |
基础医学 | 746篇 |
口腔科学 | 40篇 |
临床医学 | 762篇 |
内科学 | 976篇 |
皮肤病学 | 83篇 |
神经病学 | 740篇 |
特种医学 | 88篇 |
外科学 | 574篇 |
综合类 | 69篇 |
一般理论 | 8篇 |
预防医学 | 858篇 |
眼科学 | 135篇 |
药学 | 434篇 |
中国医学 | 6篇 |
肿瘤学 | 326篇 |
出版年
2023年 | 84篇 |
2022年 | 113篇 |
2021年 | 253篇 |
2020年 | 187篇 |
2019年 | 263篇 |
2018年 | 253篇 |
2017年 | 206篇 |
2016年 | 187篇 |
2015年 | 192篇 |
2014年 | 267篇 |
2013年 | 316篇 |
2012年 | 480篇 |
2011年 | 493篇 |
2010年 | 231篇 |
2009年 | 159篇 |
2008年 | 329篇 |
2007年 | 307篇 |
2006年 | 247篇 |
2005年 | 220篇 |
2004年 | 197篇 |
2003年 | 165篇 |
2002年 | 144篇 |
2001年 | 57篇 |
2000年 | 44篇 |
1999年 | 40篇 |
1998年 | 20篇 |
1997年 | 26篇 |
1993年 | 19篇 |
1992年 | 30篇 |
1991年 | 42篇 |
1990年 | 33篇 |
1989年 | 25篇 |
1988年 | 31篇 |
1987年 | 27篇 |
1986年 | 37篇 |
1985年 | 43篇 |
1983年 | 19篇 |
1980年 | 21篇 |
1979年 | 36篇 |
1978年 | 27篇 |
1977年 | 28篇 |
1976年 | 20篇 |
1975年 | 30篇 |
1974年 | 38篇 |
1973年 | 34篇 |
1972年 | 38篇 |
1971年 | 36篇 |
1970年 | 25篇 |
1969年 | 23篇 |
1968年 | 31篇 |
排序方式: 共有6354条查询结果,搜索用时 15 毫秒
1.
Victoria L. Parker Matthew C. Winter John A. Tidy Barry W. Hancock Julia E. Palmer Naveed Sarwar Baljeet Kaur Katie McDonald Xianne Aguiar Kamaljit Singh Nick Unsworth Imran Jabbar Allan A. Pacey Robert F. Harrison Michael J. Seckl 《International journal of cancer. Journal international du cancer》2023,152(5):986-997
Gestational trophoblastic neoplasia (GTN) patients are treated according to the eight-variable International Federation of Gynaecology and Obstetrics (FIGO) scoring system, that aims to predict first-line single-agent chemotherapy resistance. FIGO is imperfect with one-third of low-risk patients developing disease resistance to first-line single-agent chemotherapy. We aimed to generate simplified models that improve upon FIGO. Logistic regression (LR) and multilayer perceptron (MLP) modelling (n = 4191) generated six models (M1-6). M1, all eight FIGO variables (scored data); M2, all eight FIGO variables (scored and raw data); M3, nonimaging variables (scored data); M4, nonimaging variables (scored and raw data); M5, imaging variables (scored data); and M6, pretreatment hCG (raw data) + imaging variables (scored data). Performance was compared to FIGO using true and false positive rates, positive and negative predictive values, diagnostic odds ratio, receiver operating characteristic (ROC) curves, Bland-Altman calibration plots, decision curve analysis and contingency tables. M1-6 were calibrated and outperformed FIGO on true positive rate and positive predictive value. Using LR and MLP, M1, M2 and M4 generated small improvements to the ROC curve and decision curve analysis. M3, M5 and M6 matched FIGO or performed less well. Compared to FIGO, most (excluding LR M4 and MLP M5) had significant discordance in patient classification (McNemar's test P < .05); 55-112 undertreated, 46-206 overtreated. Statistical modelling yielded only small gains over FIGO performance, arising through recategorisation of treatment-resistant patients, with a significant proportion of under/overtreatment as the available data have been used a priori to allocate primary chemotherapy. Streamlining FIGO should now be the focus. 相似文献
2.
3.
4.
5.
Katie Mycock Lin Zhan Gavin Taylor-Stokes Gary Milligan Debanjali Mitra 《Current oncology (Toronto, Ont.)》2021,28(1):678
Background: Palbociclib is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor used in combination with aromatase inhibitors or fulvestrant for patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2)-negative advanced/metastatic breast cancer (ABC/MBC). Palbociclib was the first CDK 4/6 inhibitor approved for HR+/HER2− ABC/MBC treatment in Canada in combination with letrozole (P+L) as an initial endocrine-based therapy (approved March 2016), or with fulvestrant (P+F) following disease progression after prior endocrine therapy (approved May 2017). The Ibrance Real World Insights (IRIS) study () collected real-world outcomes data for palbociclib-treated patients in several countries, including Canada. Methods: This retrospective chart review included women with HR+/HER2− ABC/MBC receiving P+L or P+F in Canada. Physicians reviewed medical records for up to 14 patients, abstracting demographic and clinical characteristics, treatment patterns, and clinical outcomes. Progression-free rates (PFRs) and survival rates (SRs) at 6, 12, 18, and 24 months were estimated via Kaplan–Meier analysis. Results: Thirty-three physicians examined medical records for 247 patients (P+L, n = 214; P+F, n = 33). Median follow-up was 8.8 months for P+L and 7.0 months for P+F. Most patients were initiated on palbociclib 125 mg/d (P+L, 90.2%; P+F, 84.8%). Doses were reduced in 16.6% of P+L and 14.3% of P+F patients initiating palbociclib at 125 mg/d. The PFR for P+L was 90.3% at 12 months and 78.2% at 18 months; corresponding SRs were 95.6% and 93.0%. For P+F, 6-month PFR was 91.0%; 12-month SR was 100.0%. Conclusions: Dose reduction rates were low and PFR and SR were high in this Canadian real-world assessment of P+L and P+F treatments, suggesting that palbociclib combinations are well tolerated and effective. NCT03159195相似文献
6.
7.
8.
Lori Dorfman Lawrence Wallack Katie Woodruff 《Health education & behavior》2005,32(3):320-36; discussion 355-62
Framing battles in public health illustrate the tension in our society between individual freedom and collective responsibility. This article describes how two frames, market justice and social justice, first articulated in a public health context by Dan Beauchamp, influence public dialogue on the health consequences of corporate practices. The authors argue that public health advocates must articulate the social justice values motivating the changes they seek in specific policy battles that will be debated in the context of news coverage. The authors conclude with lessons for health education practitioners who need to frame public health issues in contentious and controversial policy contexts. Specific lessons include the importance of understanding the existing values and beliefs motivating the public health change being sought, the benefits of articulating core messages that correspond to shared values, and the necessity of developing media skills to compete effectively with adversaries in public debate. 相似文献
9.
Cerebrovascular and metabolic perturbations in delayed heavy charged particle radiation injury 总被引:5,自引:0,他引:5
E H Lo K A Frankel R L Delapaz A Poljak K H Woodruff K M Brennan M H Phillips P E Valk G K Steinberg J I Fabrikant 《Brain research》1989,504(1):168-172
Focal heavy charged particle irradiation of the rabbit brain created defined lesions which were observable by nuclear magnetic resonance (NMR) and positron emission tomography (PET) imaging techniques. The lesions appeared approximately 9-11 months after left partial hemibrain irradiation with 30 Gy (230 MeV/u helium ions), and were restricted to the white matter tracts and deep perithalamic and thalamic regions. 82Rubidium PET and Gadolinium DTPA enhanced NMR imaging were used to detect blood-brain barrier perturbations. 18Fluordeoxyglucose PET studies demonstrated widespread decreases in cerebral glucose uptake in the cortex and thalamus of the irradiated hemisphere. NMR and PET imaging results correlated well with histological findings. Rabbits irradiated with 15 Gy did not demonstrate any abnormalities in the brain with sequential NMR scans through 14 months post-irradiation. 相似文献
10.
In 2002/2005, separate energy requirement equations were generated by the Institute of Medicine's (IOM) Dietary Reference Intake process for normal weight and overweight/obese children and adolescents. The current paper questions the theoretical rationale of having two sets of equations (based solely on body-weight classification): when body weight is considered, overweight and obese children and adolescents do not seem to differ from their normal weight counterparts in energy expended for basal metabolism or physical activity tasks. However, energy needs for weight maintenance among overweight/obese girls were consistently higher when predicted using the equations for overweight/obese individuals compared with those developed for normal weight individuals. In contrast, among overweight/obese boys, they were consistently lower . Although the differences are within the variability of the estimates, even theoretical support for a higher energy intake (as occurs in girls) seems unwise because of the potential contribution to a higher body mass in children who are already at risk. It is the opinion of the authors that the IOM revisit the use of two separate equations and generate one set that is appropriate for all children and adolescents. 相似文献